



Iowa Board of Pharmacy

Frequently Asked Questions: COVID-19

Last update: January 5, 2022

The Iowa Board of Pharmacy is committed to protecting the health and safety of Iowans during the current COVID-19 pandemic. The Board and staff have received many questions relating to the pandemic and its effect on the provision of pharmacy services in Iowa. On March 22, 2020, Governor Kim Reynolds issued a [Proclamation of Disaster Emergency](#) in which she temporarily suspended a number of rules relating to licensing issues with the goal of increasing the availability of health care providers in the practice of pharmacy. On March 27, 2020, the Board issued a [Response to the Governor's Proclamation](#) which provided further guidance to affected licensees.

In the months that followed, Governor Reynolds continued the regulatory relief in subsequent Proclamations of Disaster Emergency and the Board issued responses to each Proclamation, all which can be found on the Board's [COVID Information and Updates](#) webpage. Beginning with her April 30, 2021 Proclamation of Disaster Emergency, Governor Reynolds began winding down the regulatory relief provided.

On July 23, 2021, Governor Reynolds issued a new [Proclamation of Disaster Emergency](#) in which she extended the public health emergency but **did not further extend** any of the regulatory relief for professional licensure for the practice of pharmacy.

This document intends to provide information and answers to specific questions that the Board has received or anticipates receiving. These FAQs are being provided to all licensees and registrants. This information can also be found on the Board's website at pharmacy.iowa.gov on the home page under the "Health Resources and Links" section. **Please note that the Board cannot anticipate every scenario that might occur as it relates to adjusting pharmacy operations as a result of COVID-19 and the challenges that the novel coronavirus may present.** The Board anticipates pharmacists will exercise prudent professional judgment in determining how best to modify practice to provide quality pharmaceutical care to Iowans while protecting the public and pharmacy personnel.

Additional questions that are not addressed in this document may be directed to [Board Compliance Staff](#). Staff will make every effort to provide a timely response.

The COVID-19 pandemic continues to evolve. The Board anticipates continued submission of additional questions. As such, this document will be updated as additional information warrants. Please continue to check the Board’s website for updated versions. **New questions or updated answers are in red. Updates to questions relating to the extension of regulatory relief with extended Governor Proclamations are not highlighted.**

GENERAL INFORMATION / RESOURCES	7
Iowa Board of Pharmacy	7
Iowa Governor Kim Reynolds	8
Iowa Department of Public Health	8
U.S. Centers for Disease Control and Prevention (CDC)	9
Critical Point	9
National Center for Biotechnology Information, US National Library of Medicine	9
United States Pharmacopeia (USP)	9
U.S. Drug Enforcement Administration (DEA)	9
U.S. Food and Drug Administration (FDA)	10
U.S. Environmental Protection Agency (EPA)	11
U.S. Occupational Safety and Health Administration (OSHA)	11
U.S. Dept of Health and Human Services (HHS), Assistant Secretary for Preparedness and Response (ASPR)	11
Iowa Poison Control Center	11
Iowa Pharmacy Association (IPA)	11
National Community Pharmacists Association	11
American Pharmacists Association (APhA)	11
Pharmacist’s Letter	11
The Joint Commission	11
National Council for Prescription Drug Programs (NCPDP)	12
Centers for Medicare & Medicaid Services (CMS)	12
OPERATING OR CLOSING PHARMACIES	12
Question: Can our pharmacy adjust our hours of operation?	12
Question: Can our pharmacy convert to a closed-door or delivery-only operation temporarily?	12
Question: What are the Board’s expectations if a pharmacy has to close entirely?	12
Question: Does the Board have recommendations for pharmacies that continue operating?	13
Question: Can an out-of-state pharmacy which is NOT licensed in Iowa ship prescriptions to patients located in Iowa without obtaining a license?	14
Question: Can an out-of-state wholesaler or drug distributor which is NOT licensed in Iowa ship prescription drug products into Iowa?	14
PRESCRIPTION DISPENSING / DELIVERY	14

Question: Our pharmacy provides a home delivery service. Our drivers may be exposed to COVID-19 if they have to enter a home to get someone to sign for the delivery of the prescription. Do we have to get the signature? 14

Question: Our pharmacy sometimes delivers filled prescriptions to the workplace of the patient or to a caregiver's workplace. Do the filled prescriptions have to be delivered directly to the patient or caregiver, or can they be dropped off at a central location, like a reception desk? 14

Question: Our pharmacy delivers filled prescriptions to patients who reside in assisted-living facilities. Some of those facilities have asked that deliveries be dropped off at a central location, staffed by a registered nurse or licensed practical nurse. Can we do that? 15

Question: Can my pharmacy set up a "curbside delivery" service, with patients being asked to drop off written prescriptions and pick up their filled prescriptions outside of the pharmacy building? 15

PHARMACY PRACTICE (Prescription limitations, Patient Counseling, Substitution) 15

Question: We have a patient who is out of refills for a medication. We have been unable to get a response from the patient's prescriber. Can we refill the prescription without authorization? 15

Question: A patient has come to my pharmacy to get a prescription filled because the patient's regular pharmacy has closed indefinitely. My staff has also been unable to contact the prescriber due to their clinic being closed. Can I fill the prescription without getting the required transfer or new prescription from the prescriber? 16

Question: Can our pharmacy discontinue provision of face-to-face counseling? 16

Question: Is a pharmacist authorized to engage in therapeutic interchange of a medication when or if the prescribed medication is not available, without contacting the prescribing physician for authorization? 16

Question: How do I handle prescriptions which are subject to REMS laboratory testing? 16

Question: Should pharmacists continue to provide routine immunizations during the COVID-19 pandemic? 16

Question: My pharmacy has been presented with a prescription issued by a practitioner who is not currently licensed in Iowa. Is this a legal prescription? 17

Question: Is the electronic prescribing mandate waived during this state of emergency? 17

Question: Did Governor Kim Reynolds suspend the rules relating to procedures for authentication of verbal orders and standing orders? 18

CONTROLLED SUBSTANCES 18

Question: Is my pharmacy allowed to skip the signature requirement for over-the-counter sales of pseudoephedrine or over-the-counter dispensing of schedule V cough syrups? 18

Question: I heard the DEA has relaxed some of the regulations on phoned-in emergency CII prescriptions? 18

Question: If my facility or pharmacy has to temporarily relocate or expand to an alternate location due to coronavirus exposure or to expand patient capacity, how do we obtain a new CSA registration? 19

Question: I heard that the DEA has temporarily paused its regulation which limits distribution of controlled substances to another registrant to 5% of the registrant's annual dispensing/distribution? 19

Question: I heard that the DEA has temporarily authorized DEA-registered hospitals and clinics to have controlled substances delivered to and handled by a satellite hospital/clinic which is not DEA-registered?	19
Question: Can registered pharmacies postpone DEA biennial controlled substance inventories during the nationwide public health emergency declared by the Secretary of Health and Human Services on January 31, 2020, as a result of the Coronavirus Disease 2019 (COVID-19)?	20
REMOTE PROCESSING	20
Question: Will the Board allow pharmacists and technicians to work remotely from home in order to complete duties that would normally have to occur within a licensed pharmacy?	20
Question: Can pharmacists and technicians working in a pharmacy be remotely involved in the dispensing process of another pharmacy?	20
PHARMACY SERVICES FOR LONG-TERM CARE FACILITIES	21
Question: Can our pharmacy delegate stocking an automated dispensing machine used for emergency doses to a facility nurse if the facility has restricted access to the facility?	21
PHARMACIST-TECHNICIAN / PHARMACIST-INTERN RATIOS	21
Question: Will the Board allow pharmacies to exceed the pharmacist-technician ratio (in technician product verification programs) or pharmacist-pharmacist intern ratio?	21
CONTINUING EDUCATION / TRAINING	21
Question: My CPR certification is due to expire soon and the training organization has indefinitely suspended all in-person training. Will I have to discontinue administering immunizations until I can complete certification?	21
Question: The Governor's Proclamation relaxes the continuing education requirements for license renewal. Will this apply to my pharmacist license renewal this year?	21
Question: Did the Governor relax the mandatory reporter training requirements during this emergency period?	22
PHARMACIST-INTERN / PHARMACIST LICENSURE CANDIDATE ISSUES	22
Question: The Governor's Proclamation relaxes the rules relating to the completion of clinical, practical, or internship experience for licensure. How long will that be in effect?	22
Question: The Governor's Proclamation relaxes the rules relating to the completion of background checks for professional licensure. How long will that be in effect?	22
Question: I'm a pharmacist licensure applicant and have successfully completed one of the two required exams to qualify for licensure, but the testing centers have closed and I cannot take the second exam at this time. Will I lose credit for the first exam I have taken if I reach/exceed the one year requirement for passing both components?	22
Question: What is the status of the Pearson VUE testing locations?	22
Question: What is the process for a newly graduated pharmacist-intern to obtain emergency licensure under the Governor's Proclamation of Disaster Emergency?	23
PHARMACY PERSONNEL / LICENSING ISSUES	23
Question: Can I continue to have a technician trainee working in the pharmacy if their trainee registration is due to expire soon but their CPhT national exam has been postponed due to COVID-19?	23

Question: If my pharmacy needs to hire new pharmacy technicians and pharmacy support persons which are intended to be temporary positions to get through the emergency period, do we still need to register them with the Board?	23
Question: Can the pharmacy utilize store employees who are not currently registered with the Board in any capacity to assist with duties normally handled by registered pharmacy support persons, such as entering the pharmacy to assist with handling payment transactions for prescriptions?	23
Question: My pharmacy has experienced an unexpected loss of technician staff. Can my registered pharmacy support person(s) engage in technician duties to assist the pharmacist?	24
Question: Can a pharmacist that is licensed and in good standing in another state perform work inside Iowa or remotely from another state?	24
Question: The Governor's Proclamation relaxes the rules relating to license and registration renewals. How long will that be effective and can I still practice if I haven't renewed my license or registration?	24
Question: I've heard that a pharmacist whose license has expired would be able to come back to work during this pandemic. Is that true?	24
Question: A member of my staff is believed to be infected with COVID-19. When can they return to work?	24
Question: What are the recommendations for pharmacy personnel who believe they have been exposed to coronavirus?	24
Question: Is the Board waiving licensure requirements for manufacturers to ship COVID-19 point-of-care test kits into Iowa?	25
Question: Can my pharmacy or hospital order COVID-19 testing kits from a wholesale distributor that is not licensed in Iowa?	25
Question: Does the Governor's Proclamation allowing delayed renewal for licenses/registrations apply to business licenses as well (e.g., pharmacy, wholesale distributor, limited distributor, 3PL, etc.)?	25
Question: Can my pharmacy engage a nurse to assist with COVID vaccine administration?	25

PHARMACIST SCOPE OF PRACTICE and PROTOCOLS 26

Question: Will the Board be temporarily expanding the scope of practice for pharmacists so that they can perform functions like conducting COVID-19 or rapid strep tests with subsequent prescribing of appropriate antibiotics?	26
Question: If a vaccine is approved by FDA and available for administration to prevent the novel coronavirus, will pharmacists be authorized to administer the vaccine under the Board's statewide protocol?	26
Question: Following administration of a COVID vaccine, am I required to report the administration to the patient's primary care practitioner?	27
Question: Can my pharmacy conduct COVID-19 diagnostic and/or serologic tests?	27
Question: With the recent change in the Emergency Use Authorization for REGEN-COV monoclonal antibodies (mAb) and the HHS 9th PREP Act amendment, can my pharmacy administer REGEN-COV to patients?	32
Question: When FDA authorizes a COVID-19 test for point-of-care use, does that mean it is CLIA-waived?	33

- Question: Would my pharmacy be authorized to perform CLIA-waived COVID-19 testing at off-site locations? 33
- Question: I am finding a lot of COVID-19 antibody (serology) tests available online for health care professionals to order. Can my pharmacy administer these antibody tests? 33
- Question: What is Testlowa.com? 33
- Question: How can my pharmacy become a site to administer monoclonal antibodies and/or dispense COVID-19 antivirals? (NEW January 5, 2022) 34
- Question: My hospital has been allocated supplies of the COVID-19 antivirals. They are in 5-day course packs but the board's rule limits ED dispensing to no more than 72 hours. Do we need to submit a waiver? (NEW January 5, 2022) 34

HOARDING OF DRUGS / SUPPLY CHAIN ISSUES 34

- Question: Are we authorized to limit sales of over-the-counter medications and supplies, such as acetaminophen, ibuprofen, cough medicine, etc.? 34
- Question: Can I dispense more than the authorized quantity of a prescription, if refills are available? 34
- Question: Am I authorized to limit a quantity dispensed on a prescription if I am concerned about drug supply chain issues? 34
- Question: How should my pharmacy handle prescriptions being issued for hydroxychloroquine, chloroquine, ivermectin, or other medications anecdotally being used for treatment or prophylaxis of COVID-19? 35
- Question: How should my pharmacy handle requests from practitioners who want my pharmacy to distribute stock supplies of chloroquine, hydroxychloroquine, or other prescription drugs anecdotally identified as potential treatment or prophylaxis for COVID-19 for their "office use"? 35
- Question: If my pharmacy has a drug in stock that is nearing expiration or recently expired, and it is the only product I have available to dispense, can I use it? 35
- Question: My hospital is unable to procure certain drugs needed for our hospitalized COVID-19 patients which aren't showing on the FDA drug shortage list. Can we obtain these drugs from an outsourcing facility? 35
- Question: A compounding pharmacy called my hospital to offer compounded drug products that are in short supply without a patient-specific prescription. Can my hospital use this source of drug products? 36

COMPOUNDING 36

- Question: Does the Board have any recommendations concerning the possibility of shortages of garb and personal protective equipment (PPE)? 36
- Question: Is it ok for my pharmacy to delay routine media-fill testing, gloved fingertip testing, and garbing technique observation in an effort to conserve garb? 37
- Question: Can my pharmacy compound prescription medications that are essentially copies of FDA-approved, commercially available products if they are on backorder or not available? 37
- Question: Given shortages of hand sanitizer, can pharmacies, manufacturers, and outsourcing facilities compound and sell hand sanitizer products? 37
- Question: I have heard on the news about distilleries beginning to manufacture hand sanitizer. Is this legal? 38
- Question: Can my pharmacy implement remote verification of compounding activities? 38

Question: Will the board or the FDA be enforcing the FDA's "one mile radius" limitation set in its draft Guidance for compounding within a health system?	38
Question: Will the board or FDA be enforcing the federal law which specifies a 5% limit on interstate distribution of compounded drug products?	39
Question: What is the procedure for a pharmacy that wishes to provide compounded medications to a hospital without a patient-specific prescription under the FDA's Temporary Policy?	39
TELEHEALTH ENCOUNTERS / PRESCRIPTIONS ISSUED VIA TELEMEDICINE	39
Question: If an Iowa-located health system engages with prescribers located in another state to provide remote telehealth services to Iowa patients, is the prescriber required to obtain an Iowa CSA registration prior to issuing a controlled substance prescription?	39
BOARD GENERAL OPERATIONS AND MEETINGS	40
Question: Will the Board of Pharmacy offices remain open for business and will the hours of operation remain the same?	40
Question: Will the Board's regularly scheduled meetings (Open session Board meetings, Rules Committee, Prescription Monitoring Program Advisory Council, and Monitoring Program for Pharmacy Professionals) continue to be held?	40
Question: Will I be determined to be noncompliant with my IMP3 contract if I am unable to attend meetings or practitioner appointments that are included in my contract?	40
BOARD LICENSING OPERATIONS	41
Question: Will licensees be allowed to continue operating or practicing if the Board is unable to process renewals?	41
Question: Will licensees and registrants already licensed/registered with the Board be allowed to continue practicing after their license/registration expires as a result of their inability to timely renew their license/registration due to the COVID-19 pandemic?	41
Question: Will the Board process applications for new licenses and registrations in a normal manner?	41
BOARD VARIANCE/WAIVER REQUEST REVIEWS	41
Question: Will the Board continue to process variance/waiver requests that require Board approval?	41
Question: What should licensees do if they are unable to meet the granted delay in compliance with USP Chapter facility requirements due to delays caused by responding to the COVID-19 pandemic?	41
<u>GENERAL INFORMATION / RESOURCES</u>	
<ul style="list-style-type: none"> ● Iowa Board of Pharmacy <ul style="list-style-type: none"> ○ Compounding Garb Limitations ○ Statement on Board Enforcement during COVID-19 Pandemic ○ Response to Governor's March 22 Proclamation (March 27, 2020) ○ Response to Governor's April 2 Proclamation (April 6, 2020) ○ Response to Governor's April 27 Proclamation (April 29, 2020) ○ Response to Governor's May 26 Proclamation (May 27, 2020) 	

- [Response to Governor's June 25 Proclamation \(June 26, 2020\)](#)
- [Response to Governor's July 24 Proclamation \(July 24, 2020\)](#)
- [Response to Governor's August 21 Proclamation \(August 24, 2020\)](#)
- [Response to Governor's September 18 Proclamation \(September 24, 2020\)](#)
- [Response to Governor's October 16 Proclamation \(October 19, 2020\)](#)
- [Response to Governor's November 10 Proclamation \(November 10, 2020\)](#)
- [Response to Governor's December 9 Proclamation \(December 10, 2020\)](#)
- [Response to Governor's January 7 Proclamation \(January 8, 2021\)](#)
- [Response to Governor's February 5 Proclamation \(February 8, 2021\)](#)
- [Response to Governor's March 5 Proclamation \(March 8, 2021\)](#)
- [Response to Governor's April 2 Proclamation \(April 5, 2021\)](#)
- [Response to Governor's April 30 Proclamation \(May 5, 2021\)](#)
- [Response to Governor's May 27 Proclamation \(June 1, 2021\)](#)
- [Response to Governor's June 25 Proclamation \(June 29, 2021\)](#)
- [Response to Governor's July 23 Proclamation \(July 26, 2021\)](#)
- Iowa Governor Kim Reynolds
 - [State of Public Health Disaster Emergency \(March 17, 2020\)](#)
 - [Proclamation of Disaster Emergency \(March 22, 2020\)](#)
 - [Proclamation of Disaster Emergency \(April 2, 2020\)](#)
 - [Proclamation of Disaster Emergency \(April 27, 2020\)](#)
 - [Proclamation of Disaster Emergency \(May 26, 2020\)](#)
 - [Proclamation of Disaster Emergency \(June 25, 2020\)](#)
 - [Proclamation of Disaster Emergency \(July 24, 2020\)](#)
 - [Proclamation of Disaster Emergency \(August 21, 2020\)](#)
 - [Proclamation of Disaster Emergency \(September 18, 2020\)](#)
 - [Proclamation of Disaster Emergency \(October 16, 2020\)](#)
 - [Proclamation of Disaster Emergency \(November 10, 2020\)](#)
 - [Proclamation of Disaster Emergency \(December 9, 2020\)](#)
 - [Proclamation of Disaster Emergency \(January 7, 2021\)](#)
 - [Proclamation of Disaster Emergency \(February 5, 2021\)](#)
 - [Proclamation of Disaster Emergency \(March 5, 2021\)](#)
 - [Proclamation of Disaster Emergency \(April 2, 2021\)](#)
 - [Proclamation of Disaster Emergency \(April 30, 2021\)](#)
 - [Proclamation of Disaster Emergency \(May 27, 2021\)](#)
 - [Proclamation of Disaster Emergency \(June 25, 2021\)](#)
 - [Proclamation of Disaster Emergency \(July 23, 2021\)](#)
 - [Proclamation of Disaster Emergency \(August 19, 2021\)](#)
 - [Proclamation of Disaster Emergency \(September 17, 2021\)](#)
 - [Proclamation of Disaster Emergency \(October 15, 2021\)](#)
- Iowa Department of Public Health
 - [Novel Coronavirus \(COVID-19\)](#)
 - [Isolation Guidance for Essential Services Personnel](#)
 - [Isolation Guidance for Iowans](#)
 - [What is Self Isolation?](#)

- [Iowa Statewide Emergency Registry of Volunteers \(i-SERV\)](#)
- [COVID-19 Outbreak Guidance for Businesses \(April 8, 2020\)](#)
- [IDPH Coronavirus information](#)
- [IDPH COVID-19 Vaccine Information \(October 1, 2020\)](#)
- [IDPH COVID-19 Monoclonal Antibody Therapeutics Information for Providers](#)
- U.S. Centers for Disease Control and Prevention (CDC)
 - [Coronavirus \(COVID-19\)](#)
 - [Interim US Guidance for Risk Assessment and Public Health Management of Healthcare Practitioners with Potential Exposure in Health Care Setting to Patients with Coronavirus Disease 2019 \(COVID-19\) \(Updated March 2021\)](#)
 - [Considerations for Pharmacies During the COVID-19 Pandemic \(April 3, 2020\)](#)
 - [Implementing Safety Practices for Critical Infrastructure Workers Who May Have Had Exposure to a Person with Suspected or Confirmed COVID-19 \(April 8, 2020\)](#)
 - [Considerations for Pharmacies during the COVID-19 Pandemic \(April 14, 2020\)](#)
 - [Guidance for Pharmacists and Pharmacy Technicians in Community Pharmacies during the COVID-19 Response \(Updated May 28, 2020\)](#)
 - [COVID-19 Vaccine: Quick Reference Guide for Healthcare Professionals \(March 26, 2021\)](#)
 - [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States \(March 5, 2021\)](#)
 - [Resuming Business Toolkit \(May 21, 2021\)](#)
 - [Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 \(COVID-19\) Pandemic \(September 10, 2021\)](#)
- Critical Point
 - [Critical Point Peer Network](#)
- National Center for Biotechnology Information, US National Library of Medicine
 - [WHO Guidelines on Hand Hygiene in Health Care \(hand sanitizer formulation\)](#)
- United States Pharmacopeia (USP)
 - [Compounding Alcohol-Based Hand Sanitizer During COVID-19 Pandemic \(Updated March 25, 2020\)](#)
 - [USP Response to Shortages of Garb and Personal Protective Equipment \(PPE\) for Sterile Compounding During COVID-19 Pandemic](#)
 - [USP COVID-19 Response Hand Sanitizer Information \(May 4, 2020\)](#)
 - [Operational Considerations for Sterile Compounding During COVID-19 Pandemic \(December 15, 2020\)](#)
 - [USP COVID-19 Vaccine Handling Toolkit \(January 28, 2021\)](#)
- U.S. Drug Enforcement Administration (DEA)
 - [COVID-19 Information Page](#)
 - [DEA Guidance re: Oral Emergency CII Prescriptions \(March 27, 2020\)](#)
 - [DEA Letter to Hospitals/Clinics, Manufacturers, and Distributors \(April 10, 2020\)](#)
 - [DEA Letter to Practitioners/Dispensers re: Temporary Suspension of 5% Distribution Regulation \(April 13, 2020\)](#)

- U.S. Food and Drug Administration (FDA)
 - [Coronavirus \(COVID-19\) Update: FDA Alerts Consumers About Unauthorized Fraudulent COVID-19 Test Kits \(March 20, 2020\)](#)
 - [Coronavirus \(COVID-19\) Update: FDA Provides Update on Patient Access to Certain REMS Drugs during COVID-19 Public Health Emergency \(March 22, 2020\)](#)
 - [Coronavirus \(COVID-19\) Update: FDA Helps Facilitate Veterinary Telemedicine During Pandemic \(March 24, 2020\)](#)
 - [Coronavirus \(COVID-19\) Update: FDA Takes Action to Increase U.S. Supplies through Instructions for PPE and Device Manufacturers \(March 24, 2020\)](#)
 - [Temporary Policy for Manufacture of Alcohol for Incorporation into Alcohol-based Hand Sanitizer Products during the Public Health Emergency \(COVID-19\) Guidance for Industry \(March 25, 2020\)](#)
 - [FDA announcement of the December 31, 2021 withdrawal of this temporary policy](#)
 - [FDA adds Hydroxychloroquine to Category 1 for Compounding with Bulk Drug Substances under 503B \(March 25, 2020\)](#)
 - [Emergency Use Authorization for Use of Chloroquine or Hydroxychloroquine Supplied from the SNS for Treatment of COVID-19 \(March 28, 2020\)](#)
 - [Safely Using Hand Sanitizer \(March 30, 2020\)](#)
 - [Coronavirus Disease 2019 \(COVID-19\) Frequently Asked Questions \(March 30, 2020\)](#)
 - [Coronavirus \(COVID-19\) | Drugs](#)
 - [Coronavirus \(COVID-19\) Update: Serological Tests \(April 7, 2020\)](#)
 - [Summary of Best Practices for Retail Food Stores, Restaurants, and Food Pick-Up/Delivery Services During the COVID-19 Pandemic \(April 10, 2020\)](#)
 - [Temporary Policy Regarding NonStandard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency \(April 10, 2020\)](#)
 - [Coronavirus \(COVID-19\) Update: FDA Issues Emergency Use Authorization to Decontaminate Millions of N95 Respirators \(April 12, 2020\)](#)
 - [Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency \(April 20, 2020\)](#)
 - [Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency \(April 22, 2020\)](#)
 - [Coronavirus \(COVID-19\) Update: FDA Reiterates Importance of Close Patient Supervision for 'Off-Label' Use of Antimalarial Drugs to Mitigate Known Risks, Including Heart Rhythm Problems \(April 24, 2020\)](#)
 - [Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act During the COVID-19 Public Health Emergency \(April 30, 2020\)](#)
 - [Coronavirus \(COVID-19\) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment \(May 1, 2020\)](#)

- [Temporary Policy Regarding NonStandard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency \(May 14, 2020\)](#)
- [Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency \(Revised May 21, 2020\)](#)
- [Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency \(Revised May 21, 2020\)](#)
- [Temporary Policy for Manufacture of Alcohol for Incorporation Into AlcoholBased Hand Sanitizer Products During the Public Health Emergency \(COVID-19\) \(Updated June 1, 2020\)](#)
 - [FDA announcement of the December 31, 2021 withdrawal of this temporary policy](#)
- [Medical Device Shortages During the COVID-19 Public Health Emergency \(August 14, 2020\)](#)
- [Beware of Fraudulent Coronavirus Tests, Vaccines and Treatments \(September 21, 2020\)](#)
- [A Closer Look at COVID-19 Diagnostic Testing \(November 16, 2020\)](#)
- U.S. Environmental Protection Agency (EPA)
 - [EPA Announces Enforcement Discretion Policy for COVID-19 Pandemic \(March 26, 2020\)](#) - NOTE: [Policy terminated August 31, 2020](#)
- U.S. Occupational Safety and Health Administration (OSHA)
 - [Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace \(June 10, 2021\)](#)
- U.S. Dept of Health and Human Services (HHS), Assistant Secretary for Preparedness and Response (ASPR)
 - [COVID-19: 2019 Novel Coronavirus Disease](#)
- Iowa Poison Control Center
 - [POISON ALERT: Serious Toxicity from Chloroquine and Hydroxychloroquine \(March 25, 2020\)](#)
- Iowa Pharmacy Association (IPA)
 - [COVID-19 Resources](#)
- National Community Pharmacists Association
 - [NCPA Coronavirus Information \(Updated June 2021\)](#)
- American Pharmacists Association (APhA)
 - [COVID-19 Resources and Training For You](#)
 - [COVID-19: Practice Resources](#)
 - [COVID-19 Testing In Pharmacies \(July 2021\)](#)
- Pharmacist's Letter
 - [TPL Therapeutic Substitution resources](#)
- The Joint Commission
 - [Coronavirus \(COVID-19\) Information and Resources](#)

- National Council for Prescription Drug Programs (NCPDP)
 - [NCPDP Emergency Preparedness Information](#)
- Centers for Medicare & Medicaid Services (CMS)
 - [Medicare Pharmacies and Other Suppliers May Temporarily Enroll as Independent Clinical Diagnostic Laboratories to Help Address COVID-19 Testing \(May 8, 2020\)](#)
 - [CMS and CDC announce provider reimbursement available for counseling patients to self-isolate at time of COVID-19 testing \(July 31, 2020\)](#)

OPERATING OR CLOSING PHARMACIES

Question: Can our pharmacy adjust our hours of operation?

Answer: Yes. The Board's rules do not mandate that your pharmacy be open a minimum number of hours or days. It is highly recommended that you provide updated information as far in advance and to the extent possible to your patients. For a telepharmacy operation, the hours of operation of the telepharmacy site are required to be in the agreement with the managing pharmacy, so the sites are encouraged to be in communication with each other and patients to modify hours of operation.

Question: Can our pharmacy convert to a closed-door or delivery-only operation temporarily?

Answer: Yes. The Board's rules do not require a general pharmacy license to be open to the public. The pharmacy is encouraged to provide advanced notice, to the extent possible, to the pharmacy's patients and prescribers, as well as signage on the pharmacy exterior to provide information to customers.

Question: What are the Board's expectations if a pharmacy has to close entirely?

Answer: If a pharmacy is going to close entirely:

- The pharmacist-in-charge or owner should notify [Board staff](#) prior to the closing, or as soon as possible after closing (if prior notification is not reasonably possible).
- Patients should be notified prior to the closing, or as soon as possible after closing (if prior notification is not reasonably possible). The notification should provide information about how patients can have their prescription(s) transferred or instruct that they will need to obtain new prescriptions from their provider to be filled at a different pharmacy.
- Clinics, hospitals, and prescribing practitioners from which the pharmacy receives prescriptions should be notified to the extent reasonably possible.
- If the pharmacy plans to reopen at a later date, the above notifications should include the anticipated reopening date.

Question: Does the Board have recommendations for pharmacies that continue operating?

Answer: In addition to the recommendations elsewhere in this document, pharmacies should consider the following actions when staff are working in a pharmacy that remains open to the public:

- Encourage customers to buy over-the-counter medications (without hoarding) and to refill prescriptions before they become exposed to or infected with COVID-19 (keeping in mind that *individuals do not always know if they have been exposed or infected*).
- Establish a process for reducing or eliminating the amount of time customers wait in line to pick up filled prescriptions - especially those who are at most risk. Suggestions include:
 - Maximize (or require) use of drive-through window(s) or implement curbside pick up options
 - Initiate an appointment process for prescription pick up
 - Limit the number of patients that can be in the pharmacy area at one time
 - Initiate prescription delivery services (note that prescription delivery is a task that does not require Board registration)
- Implement infection control procedures:
 - When possible, staff should maintain a distance of 6 feet from patients or other staff members; some pharmacies have placed tape on the floor in 6-foot increments to distance customers from each other
 - Require patient mask use if observed to be symptomatic
 - Regularly clean and disinfect counters, waiting areas, and other spaces - especially where public interaction occurs.
 - Place alcohol-based hand sanitizer with at least 60% isopropyl alcohol or ethyl alcohol next to the cash register or check-out area so people can sanitize their hands after using common items, like pens.
 - Staff should wash hands with soap and warm water frequently and for at least 20 seconds. (You can download and print: [IDPH Hand Washing Sign](#))
 - Staff should avoid touching eyes, nose, and mouth.
 - Staff should cover coughs and sneezes with a tissue and discard.
 - Regularly monitor all staff for illness. Staff members should stay home if they have symptoms of any respiratory infection.
 - Some businesses have put in place temporary barriers to limit transmission when customer distance cannot be at least 6 feet, such as plexiglass barriers and hanging clear plastic shower liners.
 - Consider limiting the number of patrons allowed in the store at any given time.
- Identify staffing contingency plans sooner than later to identify temporary staff that could be called to work in the event existing staff is unavailable due to illness.
- Ensure pharmacy policies and procedures are current and readily available should temporary personnel be utilized and current staff is not available to provide needed information.
- Review [CDC COVID-19 web page](#) for the most current recommendations.
- Review [Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 \(COVID-19\) Pandemic](#) for updated guidance from CDC.

Question: Can an out-of-state pharmacy which is NOT licensed in Iowa ship prescriptions to patients located in Iowa without obtaining a license?

Answer: No. A pharmacy intending to ship prescriptions to Iowans in this state must continue to hold an Iowa pharmacy license. If an unlicensed, nonresident pharmacy is located in a community along an Iowa border and has an existing patient who normally presents in person to pick up their medications, but is currently isolating due to COVID-19, the pharmacy may temporarily mail or deliver the medications to their patient during the period of the state of emergency.

Question: Can an out-of-state wholesaler or drug distributor which is NOT licensed in Iowa ship prescription drug products into Iowa?

Answer: No. A distributor intending to distribute drug products into this state must hold an appropriate license. A manufacturer must hold a Limited Distributor license while a wholesaler (if it meets the federal definition of a wholesaler) must hold a Wholesale Distributor license. The Board is acutely concerned about the potential for black or gray market operations which may be engaged in the distribution of counterfeit drug products and will take all necessary actions to prohibit those operations in Iowa.

PRESCRIPTION DISPENSING / DELIVERY

Question: Our pharmacy provides a home delivery service. Our drivers may be exposed to COVID-19 if they have to enter a home to get someone to sign for the delivery of the prescription. Do we have to get the signature?

Answer: No. The Board's rules do not require a patient's signature at delivery. The pharmacy may need to inquire with the patient's third-party payer to determine signature requirements and, if there are, if the payer will temporarily relax the requirement. The Iowa Pharmacy Association may also have additional information as it relates to insurer issues during this pandemic. Visit [Iowa Pharmacy Association's website](#) for more information. Additional information relating to Medicare and CMS actions can be found at [CMS Newsroom](#).

Question: Our pharmacy sometimes delivers filled prescriptions to the workplace of the patient or to a caregiver's workplace. Do the filled prescriptions have to be delivered directly to the patient or caregiver, or can they be dropped off at a central location, like a reception desk?

Answer: The Board recently adopted an amendment to 657 IAC 8.15 for delivery of prescriptions. The amended rule, effective April 29, 2020, says:

657—8.15(155A) Delivery of prescription drugs and devices. A prescription order may be delivered to a patient at any location licensed as a pharmacy. Alternatively, a pharmacy may use the mail, a common carrier, or personal delivery to deliver a prescription order to any location requested by the patient. A pharmacy that delivers prescription orders by one or more alternate methods shall have policies and procedures to ensure patient confidentiality, prescription order accountability, and proper storage of prescription orders during delivery. When counseling is required pursuant to rule 657—6.14(155A), oral counseling shall be

provided before the prescription order is delivered to the patient. Documentation of the delivery of prescription orders shall be maintained by the pharmacy for at least two years from the date of delivery. The term “patient” includes the patient and the patient’s authorized representatives.

As such, pharmacies may implement procedures as allowed by the amended rule to provide prescription delivery services to patients as they request, ensuring patient confidentiality, accountability, and proper storage of the medication(s).

Question: Our pharmacy delivers filled prescriptions to patients who reside in assisted-living facilities. Some of those facilities have asked that deliveries be dropped off at a central location, staffed by a registered nurse or licensed practical nurse. Can we do that?

Answer: Yes. Under the Board’s recently adopted amendment to 657 IAC 8.15 (see previous question for text of amended rule) for prescription delivery, the pharmacy can deliver a patient’s prescription to any location of the patient’s choice, as long as the pharmacy can ensure patient confidentiality, accountability, and proper storage of the medication(s).

Question: Can my pharmacy set up a “curbside delivery” service, with patients being asked to drop off written prescriptions and pick up their filled prescriptions outside of the pharmacy building?

Answer: Yes. The pharmacy needs to ensure the adjusted procedures ensure patient confidentiality, accountability, and proper storage of medication(s). If a patient requires counseling and the counseling was not provided in advance of the patient picking up the medication (preferable), staff working the “curbside delivery” location must gather from the patient a phone number at which the patient may be contacted for the pharmacist to call to provide counseling.

PHARMACY PRACTICE (Prescription limitations, Patient Counseling, Substitution)

Question: We have a patient who is out of refills for a medication. We have been unable to get a response from the patient’s prescriber. Can we refill the prescription without authorization?

Answer: Unless it’s a controlled substance, yes. [Iowa Code section 155A.29](#) currently authorizes pharmacists to exercise professional judgment by refilling a prescription one time without prescriber authorization *if all of the following are true:*

- a. The pharmacist is unable to contact the prescriber after reasonable effort.
- b. Failure to refill the prescription might result in an interruption of therapeutic regimen or create patient suffering.
- c. The pharmacist informs the patient or the patient’s representative at the time of dispensing, and the practitioner at the earliest convenience, that prescriber reauthorization is required.

Answer: If it’s a controlled substance, federal regulation has not been amended or lifted, to date, to allow renewal of a controlled substance prescription without prescriber authorization.

Question: A patient has come to my pharmacy to get a prescription filled because the patient's regular pharmacy has closed indefinitely. My staff has also been unable to contact the prescriber due to their clinic being closed. Can I fill the prescription without getting the required transfer or new prescription from the prescriber?

Answer: Unless it's a controlled substance, yes. [Iowa Code section 155A.29](#) currently authorizes pharmacists to exercise professional judgment by refilling a prescription one time without prescriber authorization *if all of the following are true:*

- a. The pharmacist is unable to contact the prescriber after reasonable effort.
- b. Failure to refill the prescription might result in an interruption of therapeutic regimen or create patient suffering.
- c. The pharmacist informs the patient or the patient's representative at the time of dispensing, and the practitioner at the earliest convenience, that prescriber reauthorization is required.

Question: Can our pharmacy discontinue provision of face-to-face counseling?

Answer: Yes, as long as the pharmacy has some equivalent method to provide the needed information to the patient. Board rule 8.15 requires oral counseling to occur before a prescription order is delivered to a patient in situations where counseling is required pursuant to rule 6.14.

Question: Is a pharmacist authorized to engage in therapeutic interchange of a medication when or if the prescribed medication is not available, without contacting the prescribing physician for authorization?

Answer: No. This regulatory relief provision terminated June 30, 2021.

Question: How do I handle prescriptions which are subject to REMS laboratory testing?

Answer: Please review [Coronavirus \(COVID-19\) Update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency](#) for guidance.

Question: Should pharmacists continue to provide routine immunizations during the COVID-19 pandemic?

Answer: The CDC published a general [answer to this question](#):

Q: Should any diagnostic or therapeutic interventions be withheld due to concerns about transmission of COVID-19?

A: Patients should receive any interventions they would normally receive as standard of care. Patients with suspected or confirmed COVID-19 should be asked to wear a surgical mask as soon as they are identified and be evaluated in a private room with the door closed. Healthcare personnel entering the room should use [Standard and Transmission-based Precautions](#).

Continued influenza immunizations have the potential to result in fewer patients that have influenza symptoms that could be confused for those of COVID-19. This has the potential to

reduce the number of patients seeking advice from the healthcare system, potentially requesting COVID-19 tests that will result as negative. This is equally true for other routine immunizations; anything that can contribute to fewer patient visits to prescriber offices and hospitals will allow those entities to triage patients with coronavirus exposure symptoms and care for those patients with advanced COVID-19.

The Board encourages pharmacists to continue to provide routine immunizations *if practitioners feel comfortable and those procedures can be performed according to the [CDC Infection Prevention and Control Recommendations for Patients Suspected or Confirmed Coronavirus Disease 2019 \(COVID-19\) in Healthcare Setting Guidelines](#)*.

Please pay attention to these details:

- Limit how germs enter your facility
 - If patients have respiratory symptoms, please direct them to their healthcare provider.
 - Only the patient receiving the immunization should be present with staff in the procedure room. Extra people should be minimized to the extent possible.
 - Ensure staff is familiar with recommended hand hygiene procedures; staff must perform these procedures before and after patient contact.
 - Ensure staff self-isolate if they have symptoms or have been exposed to people with COVID-19 symptoms. Staff that meet these criteria must not perform immunization procedures.
- Staff should wear required Personal Protective Equipment (PPE) since recommended physical distancing cannot be employed, which includes:
 - Gloves
 - Gowns
 - Respirator or mask
- Staff should disinfect the procedure areas immediately after finishing immunization administration.

Question: My pharmacy has been presented with a prescription issued by a practitioner who is not currently licensed in Iowa. Is this a legal prescription?

Answer: The regulatory relief provisions that authorized practitioners to practice in Iowa without a current license were largely discontinued effective July 25, 2021. Additional information is provided by the [Iowa Board of Medicine](#), [Iowa Dental Board](#), and the [Iowa Board of Nursing](#). For the duration of the Disaster Emergency, the Board will not require an unlicensed prescriber, **who is providing patient care on a temporary basis to aid in the public health emergency and** who is practicing pursuant to the appropriate professional licensing board parameters, to hold an Iowa CSA prior to issuing a prescription for a controlled substance. Pharmacies should contact the practitioner who issued the prescription if there is a question about whether the prescription is legal.

Question: Is the electronic prescribing mandate waived during this state of emergency?

Answer: The electronic prescribing mandate has not been specifically identified in any of the Governor's State of Public Health Disaster Emergency proclamations. Iowa Code provides a

number of exemptions for the mandate, including an emergency. Under current Board rule, an emergency is defined as including, *but not being limited to*, issuing a prescription to meet the immediate care needs of a patient after hours when a prescriber may not have access to their electronic prescribing system. During this current COVID-19 pandemic, workflow and operational practices may become untenable which may lead to lack of access to these prescribing systems or other significant barriers. In keeping with the current exemption for emergency situations, a practitioner may transmit a prescription via other than electronic methods in a situation that they deem is an emergency, including when they may not be able to access their electronic prescribing system. Prescribers are encouraged to seek additional guidance from their professional licensing board as those boards are tasked with enforcement of the mandate.

Question: Did Governor Kim Reynolds suspend the rules relating to procedures for authentication of verbal orders and standing orders?

Answer: Previously, but the provision has expired. The current regulatory provisions are reinstated and enforceable.

CONTROLLED SUBSTANCES

Question: Is my pharmacy allowed to skip the signature requirement for over-the-counter sales of pseudoephedrine or over-the-counter dispensing of schedule V cough syrups?

Answer: No. Further, [DEA Guidance relating to the signature requirement for pseudoephedrine logbooks](#) continues to require the signature of the purchaser.

Question: I heard the DEA has relaxed some of the regulations on phoned-in emergency CII prescriptions?

Answer: Yes, on March 27, 2020, the DEA published [Guidance relating to oral emergency CII prescriptions](#) which provides temporary exemptions to two required components of an oral emergency CII prescription. The Guidance allows prescribers to 1) submit the follow-up prescription to the pharmacy within 15 days (current regulation requires 7 days) and 2) submit the follow-up prescription via alternate methods, such as via facsimile or by a photograph or scan of the prescription sent to the pharmacy. Note that emergency prescriptions still must be transmitted directly from the prescriber to a pharmacist and that the follow-up prescription must still include all the required elements, including the notation “Authorization for Emergency Dispensing.” Pharmacists are encouraged to solicit the intended method of submission for the follow-up prescription from the prescriber during the initial phone call and document the relevant information for subsequent verification (e.g., ask the prescriber to identify how the follow-up prescription will be submitted and document the fax number or email address from which the prescription will be provided for subsequent verification).

Question: If my facility or pharmacy has to temporarily relocate or expand to an alternate location due to coronavirus exposure or to expand patient capacity, how do we obtain a new CSA registration?

Answer: A facility or pharmacy that needs to temporarily relocate or expand facilities to respond to a coronavirus exposure or increase in patient needs, the board will exercise enforcement discretion as it relates to CSA registration when the facility/pharmacy follows these steps:

- 1) obtain a [Department of Inspections and Appeals Health Care Waiver for CMS or State-Only Facilities](#) (this requirement does not apply to pharmacies),
- 2) obtain a [temporary registration from DEA](#) to handle controlled substances at the temporary location, and
- 3) notify [Board staff](#) of the situation.

Question: I heard that the DEA has temporarily paused its regulation which limits distribution of controlled substances to another registrant to 5% of the registrant's annual dispensing/distribution?

Answer: Yes, due to the COVID-19 pandemic and the challenges posed, DEA has issued this [Letter to DEA Practitioners](#) on April 13, 2020 in which it grants a temporary exception to 21 CFR 1307.11. If a registrant is compliant with all other aspects of distribution (such as security, recordkeeping, etc.), the DEA will not limit a registrant's distribution to 5% of its annual dispensing/distribution. The temporary authorization is backdated to January 1 and extends through the end of the national disaster emergency declaration. Upon the expiration of the national disaster emergency, the registrant will only have to count any distribution from that point through the end of the calendar year in its annual distribution calculation. Pharmacies should note that any distribution of prescription drug products, including controlled substances, are subject to the federal drug supply chain security act conditions, unless the distribution is an exempted transaction (such as to meet a specific patient need or in response to a public health emergency).

Question: I heard that the DEA has temporarily authorized DEA-registered hospitals and clinics to have controlled substances delivered to and handled by a satellite hospital/clinic which is not DEA-registered?

Answer: Yes, under very specific parameters, DEA will allow a DEA-registered hospital/clinic, under its existing DEA registration, to handle controlled substances at a satellite hospital/clinic location (one or more). The parameters include, but are not limited to, the satellite hospital/clinic was set up to provide temporary services connected to the public health emergency resulting from the COVID-19 pandemic, certain records are maintained, and that physical security and effective controls against diversion are maintained. Hospitals or clinics which may be subject to the DEA allowance must review and maintain compliance with the [DEA Letter to Hospitals/Clinics, Manufacturers, and Distributors \(April 10, 2020\)](#).

Question: Can registered pharmacies postpone DEA biennial controlled substance inventories during the nationwide public health emergency declared by the Secretary of Health and Human Services on January 31, 2020, as a result of the Coronavirus Disease 2019 (COVID-19)?

Answer: No. A biennial inventory is required under the Controlled Substances Act (CSA) as enacted by Congress. **21 U.S.C. 827(a)(1)** requires that "every registrant under [Subchapter I- Control and Enforcement] shall, on May 1, 1971, or as soon thereafter as such registrant first engages in the manufacture, distribution or dispensing of controlled substances, and every second year thereafter, make a complete and accurate record of all stocks thereof on hand, except that the regulations prescribed under this section shall permit each such biennial inventory (following the initial inventory required by this paragraph) to be prepared on such registrant's regular general physical inventory date (if any) which is nearest to and does not vary by more than six months from the biennial date that would otherwise apply." As such, the statutory text of the CSA requires registrants engaged in the manufacture, distribution, and dispensing of controlled substances to conduct an inventory no less often than biennially. DEA's regulations implementing this provision permit such registrants to conduct the inventory "on any date which is within two years of the previous biennial inventory date," but the regulations, like the statute, do not permit the inventory to be delayed beyond two years. **21 CFR 1304.11**. No waiver or exemption is currently in effect to excuse general compliance with this requirement for dispensers, including pharmacies. Any questions about the applicability of these requirements to a registrant's particular situation should be directed to the Diversion Control Division Policy Section at (571) 362-3260.

REMOTE PROCESSING

Question: Will the Board allow pharmacists and technicians to work remotely from home in order to complete duties that would normally have to occur within a licensed pharmacy?

Answer: Previously, but with the discontinuation of the regulatory relief in Governor Reynolds' Proclamations of Disaster Emergency and the Board's withdrawal of its statement on enforcement discretion, pharmacies are now expected to comply with all laws and rules relating to the practice of pharmacy, including the pharmacist supervision of technicians. The Board will be reviewing the issue and assessing a potential rule change to allow this practice in the future.

Question: Can pharmacists and technicians working in a pharmacy be remotely involved in the dispensing process of another pharmacy?

Answer: Yes, as long as the pharmacies involved have the appropriate hardware and software to exchange the necessary data to safely and securely perform the tasks and that work completed by technicians that would otherwise be verified by a pharmacist continues to be verified by a pharmacist.

PHARMACY SERVICES FOR LONG-TERM CARE FACILITIES

Question: Can our pharmacy delegate stocking an automated dispensing machine used for emergency doses to a facility nurse if the facility has restricted access to the facility?

Answer: Yes, if the automated dispensing machine has barcode-scanning capability.

PHARMACIST-TECHNICIAN / PHARMACIST-INTERN RATIOS

Question: Will the Board allow pharmacies to exceed the pharmacist-technician ratio (in technician product verification programs) or pharmacist-pharmacist intern ratio?

Answer: Previously, but with the Board's withdrawal of its statement on enforcement discretion, pharmacies are expected to fully comply with laws and rules relating to staffing ratios.

CONTINUING EDUCATION / TRAINING

Question: My CPR certification is due to expire soon and the training organization has indefinitely suspended all in-person training. Will I have to discontinue administering immunizations until I can complete certification?

Answer: No. Federal HHS issued a [4th amendment](#) to its PREP Act to specifically identify that the CPR training requirement in its authorizations for immunizations may be satisfied by an online program which has achieved accreditation by the ACPE, American Nurses Credentialing Center, or Accreditation Council for Continuing Medical Education. The board will recognize CPR certification with at least one of these accreditation credentials for the period of the CPR certification. While the Board's preference is that an immunizer receive a hands-on competency evaluation (some programs offer these remotely) per its rules, it will exercise enforcement discretion for individuals who attain CPR certification per the guidelines of the HHS under the PREP Act.

Question: The Governor's Proclamation relaxes the continuing education requirements for license renewal. Will this apply to my pharmacist license renewal this year?

Answer: Pursuant to 2020 Iowa Acts, House File 2627, pharmacists whose license expired on June 30, 2020 are not required to be renewed until June 30, 2021 (including completion of required continuing education).

Pursuant to Governor Reynolds' June 25, 2021 Proclamation which allows licensees to continue to extend license renewal requirements (but was not further extended beyond July 25, 2021), pharmacists whose license expires on June 30, 2021 will be required to renew their license (including completion of required continuing education) no later than August 24, 2021 without late renewal penalty.

Question: Did the Governor relax the mandatory reporter training requirements during this emergency period?

Answer: The Governor had relaxed the training requirements in various Proclamations of Disaster Emergency issued in the last year. The relief is no longer identified in a current Proclamation; therefore, mandatory reporter training reverts to the legal requirements.

PHARMACIST-INTERN / PHARMACIST LICENSURE CANDIDATE ISSUES

Question: The Governor's Proclamation relaxes the rules relating to the completion of clinical, practical, or internship experience for licensure. How long will that be in effect?

Answer: The Governor's May 27, 2021 Proclamation did not extend this regulatory relief. As such, all clinical, practical, or internship experience requirements will be enforceable in the licensure process.

Question: The Governor's Proclamation relaxes the rules relating to the completion of background checks for professional licensure. How long will that be in effect?

Answer: The Governor did not extend this regulatory relief in her May 27, 2021 Proclamation. As such, all applicants who are subject to a background check must complete the requirement prior to issuance of the license. Licensees whose license was granted with a deferred background check are required to submit their completed fingerprint packet no later than July 29, 2021. Failure to timely submit the completed fingerprint packet may result in license rescission.

Question: I'm a pharmacist licensure applicant and have successfully completed one of the two required exams to qualify for licensure, but the testing centers have closed and I cannot take the second exam at this time. Will I lose credit for the first exam I have taken if I reach/exceed the one year requirement for passing both components?

Answer: The Governor did not extend the provision which relaxed the one year limitation to complete both examinations in her May 27, 2021 Proclamation. As such, licensure candidates must complete both licensure exams within one year of successful completion of the first exam, unless they have obtained a board-approved waiver.

Question: What is the status of the Pearson VUE testing locations?

Answer: The Board has been made aware that Pearson VUE has reopened select testing locations across the country for limited testing, implementing significant measures to prevent spread of the coronavirus. Three locations are open in Iowa (western, eastern, and central Iowa). Pearson VUE has notified the board that it has reopened all of its testing centers in Iowa to full or near-full capacity.

Question: What is the process for a newly graduated pharmacist-intern to obtain emergency licensure under the Governor's Proclamation of Disaster Emergency?

Answer: In her May 27, 2021 Proclamation, Governor Reynolds did not extend this regulatory relief. As such, a newly graduated pharmacist-intern will be required to complete all licensure requirements, including both examinations, prior to being issued an Iowa pharmacist license.

PHARMACY PERSONNEL / LICENSING ISSUES

Question: Can I continue to have a technician trainee working in the pharmacy if their trainee registration is due to expire soon but their CPhT national exam has been postponed due to COVID-19?

Answer: Yes, but only for a technician trainee whose registration expired prior to July 25, 2021 **and** who was unable to sit for the national certification exam **and** who provided evidence of the barrier to sit for the exam prior to July 25 may continue to practice until such time as the trainee is able to schedule and take the national certification exam.

As of August 25, 2021, any technician trainee whose registration expired prior to July 25, 2021 shall be identified as "expired" and shall not be permitted to practice pharmacy unless the technician is a registered certified pharmacy technician. PTCB issued a [press release](#) which announced that the national technician certification exam will be available via online proctoring. Technicians are encouraged to visit [PTCB's Testing During COVID-19 information page](#) for more information.

Question: If my pharmacy needs to hire new pharmacy technicians and pharmacy support persons which are intended to be temporary positions to get through the emergency period, do we still need to register them with the Board?

Answer: Yes. The board recently adopted rulemaking to require registration of pharmacy employees prior to commencement of working in the pharmacy department. The requirement became effective July 1. The rulemaking also provides that individuals employed by a pharmacy for the purpose of prescription delivery are required to be registered as a pharmacy support person. This provision became effective May 12, 2021. **Note that all pharmacy employees may apply for license or registration via the [board's online application portal](#).**

Question: Can the pharmacy utilize store employees who are not currently registered with the Board in any capacity to assist with duties normally handled by registered pharmacy support persons, such as entering the pharmacy to assist with handling payment transactions for prescriptions?

Answer: No.

Question: My pharmacy has experienced an unexpected loss of technician staff. Can my registered pharmacy support person(s) engage in technician duties to assist the pharmacist?

Answer: Effective July 1, 2021, the board's rules will require registration of all pharmacy employees prior to commencing work in the pharmacy. The board's [online application portal](#) provides for the online application for all employee personnel. If you want to have a registered pharmacy support person perform technician duties, the individual will need to be registered as a technician trainee in advance of beginning those duties.

Question: Can a pharmacist that is licensed and in good standing in another state perform work inside Iowa or remotely from another state?

Answer (non-IA-licensed RPh working in out-of-state pharmacy): Pharmacists who work in an Iowa-licensed non-resident pharmacy may provide pharmacist services for Iowa patients without specifically holding an Iowa pharmacist license.

Answer (non-IA-licensed RPh working in Iowa pharmacy): As of July 26, 2021, a pharmacist who is working in an Iowa pharmacy shall hold an active Iowa pharmacist license.

Question: The Governor's Proclamation relaxes the rules relating to license and registration renewals. How long will that be effective and can I still practice if I haven't renewed my license or registration?

Answer: All licensees and registrants whose license/registration expired during the Proclamation period (March 18, 2020 through July 25, 2021) will have until August 24, 2021 to renew without penalty. As of August 25, 2021, all licenses/registrations which expired during the Proclamation period that have not been renewed will be changed to "expired" status.

If your license/registration is subject to the Proclamation exemption and you were assessed a late penalty fee via online renewal, please contact the appropriate [Licensing Clerk](#) for a refund.

Question: I've heard that a pharmacist whose license has expired would be able to come back to work during this pandemic. Is that true?

Answer: The provision which allowed a pharmacist whose license had expired to return to the practice of pharmacy was not extended in the Governor's July 23, 2021 Proclamation. As of July 26, 2021, every pharmacist working in an Iowa pharmacy must hold an active Iowa pharmacist license.

Question: A member of my staff is believed to be infected with COVID-19. When can they return to work?

Answer: Refer to current CDC guidance.

Question: What are the recommendations for pharmacy personnel who believe they have been exposed to coronavirus?

Answer: Refer to [IDPH Isolation Guidance for Essential Services Personnel \(March 22, 2020\)](#).

Question: Is the Board waiving licensure requirements for manufacturers to ship COVID-19 point-of-care test kits into Iowa?

Answer: The Board has not relaxed licensure requirements for entities part of the drug supply chain, as part of the Board's mission to protect the health, safety and welfare of Iowans. That said, a manufacturer which does not qualify as a wholesale distributor under federal law would be covered under the Board's Limited Distributor Licensure requirements. If the distribution is limited to "distribution of medical devices exclusively to a health care practitioner for use in the normal course of professional practice ("professional use")", licensure is optional.

Question: Can my pharmacy or hospital order COVID-19 testing kits from a wholesale distributor that is not licensed in Iowa?

Answer: If the wholesaler's distribution into Iowa is limited to medical devices (such as COVID testing kits) to a health care practitioner for use in the normal course of professional practice ("professional use"), yes. This distribution activity is covered under the Board's "optional licensure" with a Limited Distributor License. The wholesaler would not be authorized to distribute any prescription drug product (such as albuterol inhalers, etc.) without prior licensing as a wholesale distributor in Iowa.

Question: Does the Governor's Proclamation allowing delayed renewal for licenses/registrations apply to business licenses as well (e.g., pharmacy, wholesale distributor, limited distributor, 3PL, etc.)?

Answer: No. The Governor's Proclamations which have provided regulatory relief have been limited to "Professional" licenses and registrations, which are limited to individual licenses and registrations. There has been no gubernatorial waiver to expiration dates for business licenses or registrations within the healthcare industry nor has the Board entertained any waivers to the expiration dates for any business licenses or registrations.

Question: Can my pharmacy engage a nurse to assist with COVID vaccine administration?

Answer: Yes, with some considerations.

Delegation: Since a pharmacist does not have the authority to delegate medication administration to a nurse, the pharmacy should be vaccinating under Dr. Stille's (formerly Dr. Pedati's) standing order which delegates vaccine administration to a nurse (a registered nurse only, unless a registered nurse is on site to supervise a licensed practical nurse). Alternatively, if a nurse registers as a technician trainee, a pharmacist can delegate the task of administering immunizations to a technician trainee in accordance with rule 3.17, which was adopted through emergency rulemaking and took effect on July 14, 2021.

Board registration: If the nurse will be allowed access to the pharmacy, the nurse will need to be registered by the board as a pharmacy support person or a technician.

PHARMACIST SCOPE OF PRACTICE and PROTOCOLS

Question: Will the Board be temporarily expanding the scope of practice for pharmacists so that they can perform functions like conducting COVID-19 or rapid strep tests with subsequent prescribing of appropriate antibiotics?

Answer: On July 1, 2021, [SF 296](#) became effective, which authorizes pharmacist to order and administer point-of-care testing and treatment for influenza, streptococcus A, and COVID-19 to patients ages six years and older pursuant to statewide protocols developed by the board in consultation with the department of public health.

On August 31, 2021, the Board approved its statewide protocols for point-of-care test and treat for:

[Influenza](#)

[Strep A](#)

A SWP for COVID-19 test and treat is under development, but pharmacists are authorized under the 9th amendment of the PREP Act Emergency Declaration to order and administer certain COVID-19 therapeutics (monoclonal antibodies, etc.).

Question: If a vaccine is approved by FDA and available for administration to prevent the novel coronavirus, will pharmacists be authorized to administer the vaccine under the Board's statewide protocol?

Answer: Yes. When a vaccine is approved by FDA and added to the ACIP recommendation guidelines, a pharmacist is authorized to administer the vaccine to a patient pursuant to the Board's statewide protocol for immunizations. Under the Board's statewide protocol, a pharmacist is authorized to administer to patient's six months of age and older "other immunizations in response to a public health emergency." Beyond a state or federal public health emergency, COVID vaccines would be authorized only via a patient-specific prescription or the board-approved statewide protocol.

Additionally, HHS issued Guidance that pharmacists are authorized to order and administer all vaccinations, including one for COVID-19, once authorized or approved, to patients 3 years old and older. This authorization supersedes state authorization. The authorization requires the immunizer be compliant with state laws and regulations, including checking the statewide immunization registry and reporting requirements. The authorization also requires pharmacists to have completed two hours of continuing education in immunizations during their license renewal period.

On September 29, 2020, the Iowa Department of Public Health issued a [letter to all health care providers](#) about enrollment in the COVID-19 Vaccination Program. Any health care provider who wishes to participate in the Vaccination Program must complete the [CDC COVID-19 Vaccination Program Provider Agreement](#). At the link to the Provider Agreement, a health care provider can access a PDF version of the Agreement, but note that the Provider Agreement may only be

submitted via the online survey. All providers who participate in the Vaccination Program are required to submit documentation of the administration to the state's vaccine registry. The Provider Agreement provides more information about the parameters of participating in the Program. The Board encourages pharmacies to participate in the COVID-19 Vaccination Program to the extent possible, if the pharmacy has appropriate resources to do so. A statewide standing order for COVID vaccinations can be found [HERE](#). Interim Director Garcia has issued a vaccine shortage order which can be found [HERE](#).

More information about the COVID-19 Vaccination Program can be found at [IDPH COVID-19 Vaccine Information](#).

On October 20, 2020, HHS issued [Guidance](#) that authorizes qualified pharmacy technicians and State-registered pharmacy interns to administer childhood vaccines to patients ages 3 through 18 as well as COVID-19 vaccines to patients ages 3 and above. The Board issued further [Guidance](#) on the implementation of technician immunization.

COVID Vaccine Program participating pharmacies which are experiencing shortages of PPE and supplies to support vaccine administration may reach out to their [Homeland Security and Emergency Management County Coordinator](#) for potential access to needed supplies from the state strategic stockpile.

The Board encourages pharmacies to review their emergency kit to ensure adequate supplies of non-expired medications are available for adverse reactions to an immunization and encourages pharmacies to ensure patients remain under observation for an adequate period of time to ensure no emergency adverse reaction occurs.

Question: Following administration of a COVID vaccine, am I required to report the administration to the patient's primary care practitioner?

Answer: It depends.

- If the administration is pursuant to Dr. Stilley's order, the pharmacist/pharmacy is **not** required to report the administration of the vaccine (due to being for a public health emergency). See 657 IAC 39.10(7)"b"
- If the administration is pursuant to the Board's statewide protocol or the HHS order authorizing pharmacists to order and administer the vaccine, state law must be followed which requires reporting to the primary care practitioner, if known, "as soon as reasonably possible". See Iowa Code 155A.46(2)"b" and 657 IAC 39.11(5)

Question: Can my pharmacy conduct COVID-19 diagnostic and/or serologic tests?

Answer: Yes. The PREP Act and subsequent [HHS Guidance](#) authorize pharmacists to order and administer COVID testing, including serology tests, authorized by FDA. This authority provides pharmacists with the independent authority to order and administer a test without a specific order from a prescriber to do so. This authority extends only through the federal government's designation of the public health disaster. Pharmacist administration of COVID testing beyond the

federal public health disaster must be pursuant to an order by a licensed healthcare practitioner authorized to prescribe.

Types of tests which can be ordered and administered by pharmacists

The HHS Guidance authorizes pharmacists to order and administer COVID tests *which are authorized by FDA*. The pharmacist must ensure that the test to be administered is authorized by FDA either under a normal approval process or through the [FDA's Emergency Use Authorization](#) process. *Pharmacists are not authorized to order and administer a COVID-19 test which has not received FDA authorization, even if it may be available in the marketplace.*

- *Diagnostic COVID-19 Testing at the Point-of-Care / Patient Care Setting (Pharmacy)*

There are multiple molecular diagnostic tests authorized by FDA to be used at the point-of-care. Special testing information about the use of the Abbott ID NOW can be found [HERE](#).

There are multiple antigen diagnostic tests authorized by FDA to be used at the point-of-care.

- *Diagnostic COVID-19 Testing at Laboratory with Specimen Collection at Pharmacy*

There are currently many diagnostic tests authorized by FDA to be processed by a moderate or high-complexity CLIA laboratory. The pharmacy would collect the patient's respiratory specimen at the pharmacy (the type of respiratory specimen collected would be determined by the test kit to be used and could include a simple nasal swab or more invasive nasopharyngeal swab) and send the specimen to a moderate or high-complexity laboratory for testing (the complexity of the lab would be determined by the test kit to be used).

- *Diagnostic COVID-19 Testing at Laboratory with Specimen Collection at Patient's Home*

There are several diagnostic tests authorized by FDA which authorize at-home specimen collection. The [FDA website for EUAs](#) includes the tests which are authorized for at-home specimen collection.

- *Serologic COVID-19 Testing at the Point-of-Care / Patient Care Setting (Pharmacy)*

There is at least one COVID-19 serology test authorized by FDA to be used at the point-of-care in a location with a CLIA Certificate of Waiver ([Assure](#)). It should be noted that the Iowa Department of Public Health cautions against using tests that simply require a finger stick specimen in the absence of rigorous testing to ensure the tests are accurate and reliable in their results.

- *Serologic COVID-19 Testing at Laboratory with Specimen Collection at Pharmacy*

There are currently several COVID-19 serology tests authorized by FDA to be processed by a moderate- or high-complexity CLIA laboratory. Unless the pharmacy has attained a CLIA Certificate of Compliance, the pharmacy would collect the patient's blood specimen at the pharmacy (the type of blood specimen collected would be determined by the test kit to be used, likely a venipuncture sample) and send the specimen to a moderate- or high-complexity laboratory for testing (the complexity of the lab would be determined by the test kit to be used). It should be noted that the Iowa Department of Public Health cautions against using tests that simply require a finger stick specimen in the absence of rigorous testing to ensure the tests are accurate and reliable in their results.

Delegation of tasks to technicians

As pharmacists consider engaging in any type of COVID-19 testing, they should continue to comply with laws and rules relating to pharmacist responsibilities for dispensing, delegation of tasks, and supervision of pharmacy personnel. Pharmacists are authorized to independently order and administer COVID-19 tests, and to dispense a test ordered by another provider, including another pharmacist. Pharmacists may delegate appropriate non-clinically judgemental tasks associated with testing to pharmacy personnel who are appropriately trained and working under pharmacist supervision.

On October 20, 2020, HHS issued [Guidance](#) that authorizes qualified pharmacy technicians and State-registered pharmacy interns to administer COVID-19 tests. The Board issued this [Guidance](#) to provide further information to licensees.

Laboratory information

- *Point-of-care testing (POCT)*: If a pharmacy intends to order and administer POCT, it must first have a current [CLIA Certificate of Waiver](#) to conduct CLIA-waived tests, such as POCT for COVID-19. A pharmacy that does not have a CLIA Certificate of Waiver may complete the [Clinical Laboratory Improvement Amendments \(CLIA\) Application for Certification \(CMS Form 116\)](#) and submit to the:

Iowa CLIA Laboratory Program
State Hygienic Laboratory
University of Iowa Research Park
2490 Crosspark Road
Coralville, IA 52241
(319) 335-4500 or (800) 421-IOWA
FAX: (319) 335-4174
Email: shl.clia@uiowa.edu

On the application for a CLIA Certificate of Waiver, the pharmacy may be required to identify the specific CLIA-waived test(s) intended to be administered at the pharmacy.

- *Moderate- or High-Complexity testing:* Pharmacy collection of patient specimens (respiratory for diagnostic, venous blood for serologic) for subsequent moderate- or high-complexity lab analysis must identify and coordinate with a laboratory for such testing. No CLIA Certificate of Compliance or Waiver is required for specimen collection. Possible laboratory options may include, but cannot be guaranteed by the Board:
 - [Quest Diagnostics](#)
 - [ARUP](#)
 - [LabCorp](#)
 - [State Hygienic Lab](#)

Policies and Procedures

The pharmacy must ensure that, depending on the test(s) to be conducted, a complete policy and procedure is established and followed which includes but is not limited to:

- Notification of the pharmacy’s intent to order and administer COVID-19 tests via updating the pharmacy’s online profile with the Board via [View User Profile and Update Demographics](#) to identify “COVID-19 Diagnostic” or “COVID-19 Antibody” testing as an available pharmacy service;
- Notification to the test kit manufacturer and FDA (via email at CDRH-EUA-Reporting@fda.hhs.gov) of any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the test kit;
- Patient screening parameters prior to ordering and administering a test, including identification of testing priority groups;
- Personnel training required prior to engaging in specimen collection and testing, including review and understanding of the test kit manufacturer instructions / package insert;
- Strict adherence to the testing procedure identified in the test kit manufacturer instructions / package insert;
- Appropriate use of personal protective equipment (PPE);
- Environmental security measures that will be in place to prevent the spread or transmission of the coronavirus by a potentially infected individual presenting to the testing site;
- Evaluation of test results;
- Dissemination of test results to the patient, the patient’s primary care practitioner, and the local public health agency; and
- Patient guidance to be provided based on the test type (diagnostic or serologic) and test result (positive or negative).

Personnel Training

Pharmacy personnel who will be conducting COVID-19 testing must be properly trained on the testing policy and procedures, proper specimen collection, proper use of personal protective equipment (PPE), and evaluation of test results prior to engaging in specimen collection and/or testing. Documentation of completed training, and documented observed competency for

specimen collection and use of PPE, for each individual involved in specimen collection and/or testing must be maintained in the pharmacy and available for inspection and copying by the Board or its authorized representative.

Supplies for Collection of Patient Specimens

A pharmacy engaged in COVID-19 testing, either at POC or collection of specimens for moderate- or high-complexity laboratory testing, which is having difficulty obtaining supplies for collecting patient specimens should review the FDA website [Contacts for Medical Devices During the COVID-19 Pandemic](#) for more information.

Test Result Reporting

A pharmacy engaged in ordering or analyzing COVID-19 tests (including at POC, collection of specimens for moderate- or high-complexity laboratory testing, or ordering a test for a patient's at-home specimen collection and submission to a moderate or high-complexity laboratory) must provide all test results to the patient, the patient's primary care practitioner (if identified), and to the Iowa Department of Public Health (electronically through the Iowa Disease Surveillance System, preferred, or via fax to 515-281-5698). If the pharmacy is only involved with overseeing specimen collection but is not the ordering practitioner or lab conducting the test analysis, the pharmacy is not required to report test results.

The pharmacy, regardless of the pharmacy's level of involvement in testing, must update the pharmacy's online profile with the Board via [View User Profile and Update Demographics](#) to identify the pharmacy's service(s) of "COVID-19 Diagnostic" and/or "COVID-19 Antibody" testing. Within approximately 48 hours, the pharmacy will receive via email a template to use for submission of test results to the IDSS, if the pharmacy is required to report based on the pharmacy's level of involvement in testing. If the pharmacy has not received the template within 72 hours, please contact sue.mears@iowa.gov.

Treatment Following a Positive COVID-19 Test Result

At this time, there is no Board-approved statewide protocol for test and treat for COVID-19. However, under the 9th Amendment to the PREP Act Emergency Declaration, pharmacists are authorized to order and administer approved or authorized COVID-19 therapeutics that are administered subcutaneously, intramuscularly, or orally in accordance with the EUA.

Billing to CMS

The US Centers for Medicare & Medicaid Services (CMS) recently published information allowing pharmacies to [temporarily enroll as an independent clinical diagnostic laboratory](#) for the purpose of reimbursement for COVID-19 testing. Note that the information and subsequent enrollment does not impact or override the CLIA requirements for laboratories. Pharmacies would still be limited to conducting tests that are authorized for their level of CLIA certification.

On July 31, 2020, [CMS and CDC announced](#) that provider reimbursement is available for counseling patients to self-isolate at the time of the COVID testing. Providers who are eligible to bill CMS for counseling services will be able to use existing evaluation and management (E/M) payment codes for reimbursement. Further information and resource links are available in the [Counseling Check List PDF](#).

Final Reminder

A pharmacy engaged in COVID-19 testing must continue to be aware of current recommendations and [authorizations](#) for such testing. While the HHS Guidance issued April 8, 2020 provides pharmacists immunity from damages as a result of conducting COVID-19 countermeasures, the Board's expectation is that pharmacists are conducting these tests under strict policy and procedures and adhering to the test kit product insert.

Question: With the recent change in the Emergency Use Authorization for REGEN-COV monoclonal antibodies (mAb) and the HHS 9th PREP Act amendment, can my pharmacy administer REGEN-COV to patients?

Answer: Yes. The [HHS 9th Amendment to the PREP Act Declaration](#) authorizes pharmacists to order and administer and technicians and interns to administer any COVID-19 therapeutic that is approved or authorized by the FDA which is administered orally, intramuscularly or subcutaneously.

- Training. The pharmacist, technician or intern who is administering the COVID-19 therapeutic must complete an ACPE-approved practical training program which includes:
 - Hands-on injection technique,
 - Clinical evaluation of indications and contraindications of COVID-19 therapeutics,
 - Recognition and treatment of emergency reactions to COVID-19 therapeutics, and
 - Any other training identified by FDA.
- Supervision. A supervising pharmacist must be readily and immediately available to the technician.
- CPR certification. The pharmacist, technician or intern must hold a current certification in basic cardiopulmonary resuscitation.
- Recordkeeping and reporting.
 - Pursuant to Iowa Code 155A.46, subsection 2, paragraphs (a) and (b), the pharmacy must retain records of the medication ordered and administered and notify the patient's primary care provider.
 - Pharmacies must report the administration to HHS weekly via <https://teletracking.protect.hhs.gov>
- Board notification. A pharmacy intending to order and administer COVID-19 therapeutics must update its online board pharmacy profile (link [HERE](#)) and indicate "Yes" to the pharmacy service "Statewide Protocol - COVID-19 Test and Treat" (regardless of administration under the HHS PREP Act authority or a board-approved SWP, if available).

- Product availability. As of September 13, 2021, mAb distribution is being handled via federal and state-level allocation and distribution. Pharmacies that wish to be an approved provider of mAbs must complete the [IDPH COVID-19 Monoclonal Antibody Provider Request Form](#).

Question: When FDA authorizes a COVID-19 test for point-of-care use, does that mean it is CLIA-waived?

Answer: Yes. When the FDA issues a Letter of Authorization to a company to authorize a COVID-19 test under an Emergency Use Authorization, the letter will include the settings in which the EUA-authorized test may be performed. When FDA authorizes point-of-care tests (including for SARS-CoV-2) under an EUA, such tests are deemed to be CLIA-waived and can be performed in a patient care setting that is qualified to have the test performed there as a result of operating under a CLIA Certificate of Waiver.

Question: Would my pharmacy be authorized to perform CLIA-waived COVID-19 testing at off-site locations?

Answer: Yes. Information provided in [How to Obtain a CLIA Certificate of Waiver](#) information, CLIA-waived tests can be provided at temporary locations.

Question: I am finding a lot of COVID-19 antibody (serology) tests available online for health care professionals to order. Can my pharmacy administer these antibody tests?

Answer: While there are several COVID-19 antibody tests authorized for use by FDA under an [Emergency Use Authorization](#) (“EUA”), the vast majority of which are only authorized for use in a moderate or high-complexity laboratory. FDA has relaxed its regulatory framework for development of these tests, allowing companies to develop and market test kits prior to receiving official approval from FDA. The companies are required to validate their test results prior to marketing their tests and are required to notify the FDA of their validation and intent to distribute. However, until a test kit has been authorized by FDA (either under the regular approval process or via an EUA), such test kit has not been assigned a CLIA designation. As such, *test kits which do not have FDA approval or FDA EUA that specifies use in a CLIA-waived lab are deemed to be conducted only in a high-complexity laboratory environment and, therefore, not approved for use at the point of care or patient care setting, such as in a pharmacy.*

Question: What is Testlowa.com?

Answer: [Testlowa.com](#) is an initiative by the State of Iowa to increase the rate of COVID-19 testing to expand access to testing and help stem the spread of the coronavirus. Iowans are encouraged to visit Testlowa.com and complete the assessment. Depending on the data provided, the individual will be notified if they are eligible to be tested for COVID-19 at one of the state’s testing locations.

Question: How can my pharmacy become a site to administer monoclonal antibodies and/or dispense COVID-19 antivirals? (NEW January 5, 2022)

Answer:

- A pharmacy that meets the requirements to administer monoclonal antibodies may complete a survey [HERE](#) for consideration as an approved provider. Note, however, that as supplies are allocated in extremely limited quantities from the federal government, it is unlikely that the Department is in need of additional sites.
- A pharmacy that meets the requirements to dispense COVID-19 antiviral medications may send an email to C19therapeutics@idph.iowa.gov to express your interest in becoming a dispensing site. Department personnel will be in contact with you for additional information if and when they are looking to expand its list of pharmacy partners.

Question: My hospital has been allocated supplies of the COVID-19 antivirals. They are in 5-day course packs but the board's rule limits ED dispensing to no more than 72 hours. Do we need to submit a waiver? (NEW January 5, 2022)

Answer: No. The board's rule also provides a phrase "or the minimum quantity in suitable containers" which would cover the situation here. The ED may dispense the unit-of-use package of the complete 5-day treatment course.

HOARDING OF DRUGS / SUPPLY CHAIN ISSUES

Question: Are we authorized to limit sales of over-the-counter medications and supplies, such as acetaminophen, ibuprofen, cough medicine, etc.?

Answer: Yes. The Board has no mandate that the pharmacy sell these products, so it is entirely a business decision for the pharmacy to set purchase limitations if desired.

Question: Can I dispense more than the authorized quantity of a prescription, if refills are available?

Answer: Unless it is a controlled substance, yes. [Iowa Code section 155A.27, subsection 6](#), authorizes a pharmacist to dispense "up to the total number of dosage units authorized by the prescriber on the original prescription and any refills of the prescription, not to exceed a 90-day supply." It is recommended, however, that pharmacists exercise professional judgment in making determinations on dispensing additional quantities of prescription drugs. While it is beneficial to limit the number of pharmacy visits for patients, there is also a concern about adding to the strain of the drug supply chain.

Question: Am I authorized to limit a quantity dispensed on a prescription if I am concerned about drug supply chain issues?

Answer: Yes, you can use your professional judgment to dispense partial quantities of prescription medications in order to prevent the situation of limited drug supplies.

Question: How should my pharmacy handle prescriptions being issued for hydroxychloroquine, chloroquine, ivermectin, or other medications anecdotally being used for treatment or prophylaxis of COVID-19?

Answer: The Board encourages you to use your best professional judgment in determining the legitimacy of these prescriptions and the likely intent. There is no mandate to fill a prescription and a pharmacist has a corresponding responsibility to ensure that a valid patient-prescriber relationship exists and that a prescription was issued for a legitimate purpose. Prescribers are authorized to prescribe medications that are “extra-label” or “off-label” and pharmacists are encouraged to review current scientific literature, and FDA and CDC resources to find the most up-to-date information about potential treatments for COVID-19.

Question: How should my pharmacy handle requests from practitioners who want my pharmacy to distribute stock supplies of chloroquine, hydroxychloroquine, or other prescription drugs anecdotally identified as potential treatment or prophylaxis for COVID-19 for their “office use”?

Answer: Pharmacies are strongly encouraged to limit distribution of these products to only another pharmacy to meet a specific patient need (legitimate prescription for appropriate diagnosis).

Question: If my pharmacy has a drug in stock that is nearing expiration or recently expired, and it is the only product I have available to dispense, can I use it?

Answer: FDA has published information relating to [Expiration Dating Extension](#) and also publishes a list of drugs and devices subject to [Emergency Use Authorization](#).

- Review FDA’s [Search List of Extended Use Dates to Assist with Drug Shortages](#) to see if the product has been issued extended expiry by FDA. It is updated daily with information obtained from manufacturers. To request extended expiry for a drug, send an email to DRUGSHORTAGES@fda.hhs.gov, including detailed information of product(s) for the extended expiration request (NDC number, lot numbers, expiration dates, at a minimum).
- If the drug product is not approved for extended expiration and is a drug relevant to the current pandemic (such as ventilator drugs), the pharmacy may reach out to their [Local Homeland Security and Emergency Management Coordinator](#) to request supply from state resources. If the state does not have resources available, the state will elevate the request to their federal resources.

Question: My hospital is unable to procure certain drugs needed for our hospitalized COVID-19 patients which aren’t showing on the FDA drug shortage list. Can we obtain these drugs from an outsourcing facility?

Answer: Yes, under very specific conditions and parameters. On April 16, 2020, FDA issued this [Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency](#) which identifies specific drug products which will be allowed to be compounded by outsourcing facilities for hospitalized COVID-19 patients. Facilities compounding the identified drugs must adhere to the specific conditions identified in the Policy in order to be eligible for the FDA’s enforcement discretion policy. On May 8, FDA updated the Policy which adds two drugs to the list of drugs authorized under the

temporary policy. The FDA updated it once again on May 21, 2020. The current list of drugs which may be compounded pursuant to the FDA's Temporary Policy can be found [HERE](#).

Question: A compounding pharmacy called my hospital to offer compounded drug products that are in short supply without a patient-specific prescription. Can my hospital use this source of drug products?

Answer: Maybe, but use extreme caution. The FDA published a [Temporary Policy](#) which allows compounding pharmacies which are not registered as 503B outsourcing facilities to compound certain drug products for hospitals which are treating COVID-19 patients without first obtaining a patient-specific prescription, as would normally be required under the FD&C Act. Your pharmacy must exhaust all other sources of FDA-approved products before obtaining compounded products under this temporary policy (including checking FDA's searchable list of extended expiration dates; obtaining product from other Iowa-licensed dispensers, Iowa-licensed distributors, etc; and obtaining compounded products from Iowa-licensed outsourcing facilities). The hospital must ensure the compounding pharmacy is licensed in Iowa and should ensure the compounding pharmacy has obtained notification from the Board that it does not object to the compounding pharmacy's provision of the compounded drug product(s). The Board would ask that hospitals which obtain drug product(s) in this manner notify the Board with any product issues or adverse events associated with the drug product(s) provided under this temporary policy. The current list of drugs which may be compounded pursuant to the FDA's Temporary Policy can be found [HERE](#).

These conditions must be met in order to use this temporary policy:

- The hospital must be treating COVID-19 patients,
- The hospital is unable to obtain the drug product(s) from other sources, including outsourcing facilities
- The drug product(s) are limited to only those listed in the FDA temporary policy,
- The BUD is assigned according to the FDA temporary policy,
- The hospital provides relevant information to the pharmacy within 30 days, and
- The compounding pharmacy notifies the state regulatory authority for compounding (board of pharmacy, generally) both in the state in which the compounding pharmacy is located as well as the state in which the hospital is located and obtains notification that the regulatory authority does not object to the provision of the drug products.

COMPOUNDING

Question: Does the Board have any recommendations concerning the possibility of shortages of garb and personal protective equipment (PPE)?

Answer: Yes. The Board issued guidance relating to this on March 9, 2020, which can be found [here](#). Since the Board's initial issuance of this guidance, additional guidance has been issued by Critical Point, USP and FDA. The Board supports the use of PPE reuse and shortage guidance put forth by any of these organizations as it applies to your facility.

The Board strongly encourages compounding personnel to utilize the resources available at the [Critical Point Peer Network](#) where you can sign up for a Silver Subscription at no charge and access valuable information relating to compounding challenges resulting from the COVID-19 pandemic.

Additionally, USP issued an information resource that might be helpful: USP Response to Shortages of Garb and Personal Protective Equipment (PPE) for Sterile Compounding During COVID-19 Pandemic which may be downloaded [HERE](#). The Board is aware that the recommendations are slightly different from those provided by Critical Point. The Board is supportive of licensees making professional judgments in their individual situation to determine the best course of action to ensure product quality, public safety, and employee protection.

On April 10, 2020, FDA issued a [Temporary Policy Regarding NonStandard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency](#) which provides that it does not intend to take enforcement action regarding compliance with the insanitary conditions provision when drugs intended or expected to be sterile are compounded without standard PPE provided the compounder is compliant with the conditions identified in the temporary policy.

Question: Is it ok for my pharmacy to delay routine media-fill testing, gloved fingertip testing, and garbing technique observation in an effort to conserve garb?

Answer: Maybe. Since media-fill testing can reasonably be completed at the end of a compounding shift, this would not require additional, unnecessary use of garb and should not be delayed. If garbing is simply for the purpose of observing the garbing and aseptic technique of compounding personnel (unless for a newly trained compounder), the observer may consider remote observation (through a window, etc.) during normal compounding operations or, if that's not reasonable, testing could be delayed.

Question: Can my pharmacy compound prescription medications that are essentially copies of FDA-approved, commercially available products if they are on backorder or not available?

Answer: Yes. Board rule [657 IAC 20.12](#) currently authorizes a pharmacist to compound a drug that is otherwise commercially available when that product is not available due to a documented drug shortage or the drug is listed on the [FDA Drug Shortages List](#).

Question: Given shortages of hand sanitizer, can pharmacies, manufacturers, and outsourcing facilities compound and sell hand sanitizer products?

Answer: Yes. Board rules would ordinarily limit a pharmacy to dispensing compounded products only pursuant to a patient-specific prescription, but FDA recently published its [Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency](#) encouraging pharmacies to engage in such compounding. The Board will exercise enforcement discretion when pharmacies and outsourcing facilities engage in compounding of hand sanitizer in compliance with FDA guidance.

Additionally, USP issued an informational resource which might be helpful: [Compounding Alcohol-Based Hand Sanitizer During COVID-19 Pandemic](#). On March 25, 2020, USP published this updated resource: [Compounding Alcohol-Based Hand Sanitizer During COVID-19 Pandemic](#).

The Board has been alerted that PCCA has a formulation that is slightly different than the FDA guidance identifies. The Board is supportive of a pharmacy using a formulation by any nationally recognized compounding authority (FDA, PCCA, etc.) as long as the pharmacy or outsourcing facility is limiting the BUD to 30 days as recommended by WHO and USP.

As it relates to manufacturers who do not already have FDA approval to produce these products, FDA released *temporary* [Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency \(COVID-19\)](#). The Board will also exercise enforcement discretion with manufacturers which are producing hand sanitizers under FDA's Guidance.

On October 12, 2021, FDA announced that it plans to withdraw this temporary policy, effective December 31, 2021.

Question: I have heard on the news about distilleries beginning to manufacture hand sanitizer. Is this legal?

Answer: At this time, FDA has issued *temporary* [Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency \(COVID-19\)](#) which establishes that FDA will not take enforcement action against a firm for this activity *if* they are strictly following the guidance for formulation, documentation, and controls.

On October 12, 2021, FDA announced that it plans to withdraw this temporary policy, effective December 31, 2021.

Question: Can my pharmacy implement remote verification of compounding activities?

Answer: Yes, see "**REMOTE PROCESSING**" section for information about systems requirements to implement product or staging verification during compounding operations.

Question: Will the board or the FDA be enforcing the FDA's "one mile radius" limitation set in its draft Guidance for compounding within a health system?

Answer: The FDA recently announced a policy clarification that its draft guidance for hospital and health system compounding is still in draft and is planned to be revised. As the Guidance has only been issued for public comment, it has not been implemented and FDA will not be enforcing a one mile radius for hospitals and hospital systems. As such, the Board will also not be enforcing a one mile radius limitation.

Question: Will the board or FDA be enforcing the federal law which specifies a 5% limit on interstate distribution of compounded drug products?

Answer: FDA recently announced a policy clarification that it will not be enforcing the federal 5% distribution limitation until such time as the Memorandum of Understanding (MOU) can be finalized and states are allowed the opportunity to sign it. As such, the Board will also not be enforcing the 5% distribution limitation. On October 26, 2020, the FDA published the [MOU](#) which will be available for state consideration for one year prior to initiating enforcement provisions of the law. On August 9, 2021, FDA published that it has extended the deadline for states to consider entering into the MOU to October 27, 2022.

Question: What is the procedure for a pharmacy that wishes to provide compounded medications to a hospital without a patient-specific prescription under the FDA's Temporary Policy?

Answer: The FDA recently issued a [Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency](#) which authorizes 503A compounding pharmacies to distribute certain compounded drug products for use in hospitalized patients with COVID-19 without first obtaining a patient-specific prescription. The Temporary Policy identifies the specific drug products covered by the Policy as well as beyond-use-dating limitations for the compounded products, among other conditions. A pharmacy which intends to distribute non-patient specific compounded drug products pursuant to the FDA Temporary Policy must first notify the Board (via email to sue.mears@iowa.gov) and provide the following information:

- Pharmacy name and address,
- Iowa pharmacy license number, and
- Drug product(s) which the pharmacy intends to distribute.

Upon review of the notification and supporting documentation, Board staff will provide a response indicating if the Board does not intend to object to the pharmacy providing the drug product(s) to the hospital(s) without first obtaining a patient-specific prescription.

TELEHEALTH ENCOUNTERS / PRESCRIPTIONS ISSUED VIA TELEMEDICINE

Question: If an Iowa-located health system engages with prescribers located in another state to provide remote telehealth services to Iowa patients, is the prescriber required to obtain an Iowa CSA registration prior to issuing a controlled substance prescription?

Answer: No, as long as the practitioner's related primary regulatory authority is not requiring an Iowa practitioner license prior to treating Iowa patients to aid in the public health emergency. Currently, the Iowa Board of Medicine is not requiring prescribers located in another state treating patients located in Iowa to first obtain an Iowa medical license. As such, a CSA will also not be required - when the practitioner is providing care to aid in the emergency. A pharmacy should check the website of the related practitioner regulatory authority to determine if the practitioner would be required to hold an Iowa license. If an Iowa prescriber license is not required under the

Governor's emergency proclamation, then no CSA will be required. Upon the expiration of the emergency proclamation, or a regulatory authority's change of interpretation, a prescriber who is located in another state treating patients in Iowa must first hold an Iowa practitioner license and, if the practitioner intends to prescribe controlled substances, must hold an Iowa CSA registration.

[DEA](#) has also announced that, as of March 16, 2020, and continuing for as long as the Secretary's designation of a public health emergency remains in effect, DEA-registered practitioners in all areas of the United States may issue prescriptions for all schedule II-V controlled substances to patients for whom they have not conducted an in-person medical evaluation, provided all of the following conditions are met:

- The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of his/her professional practice;
- The telemedicine communication is conducted using an audio-visual, real-time, two-way interactive communication system; and
- The practitioner is acting in accordance with applicable Federal and State laws.

BOARD GENERAL OPERATIONS AND MEETINGS

Question: Will the Board of Pharmacy offices remain open for business and will the hours of operation remain the same?

Answer: The Board office is currently closed to the public. A mail drop box has been placed in the front vestibule in which items for Board staff may be placed. Licensees and registrants are asked to utilize the Board's [Online Services](#) to the extent possible. Questions can be directed to [Board Staff](#). The Board's hours of operation will remain the same at this time.

Question: Will the Board's regularly scheduled meetings (Open session Board meetings, Rules Committee, Prescription Monitoring Program Advisory Council, and Monitoring Program for Pharmacy Professionals) continue to be held?

Answer: The Board resumed in-person Board meetings with the option for remote participation beginning with its July 2021 Board meeting.

Question: Will I be determined to be noncompliant with my IMP3 contract if I am unable to attend meetings or practitioner appointments that are included in my contract?

Answer: Not if you are in routine communication with the IMP3 Case Manager to keep her updated on your situation.

BOARD LICENSING OPERATIONS

Question: Will licensees be allowed to continue operating or practicing if the Board is unable to process renewals?

Answer: Yes. The Board's current rules allow continuation of operations or practice during a 30 day grace period while a renewal application is being processed. Board licensing staff will continue to process applications and the Board does not anticipate any excursion from its normal application processing times. Licensees and registrants are encouraged to utilize the Board's [Online Services](#).

Question: Will licensees and registrants already licensed/registered with the Board be allowed to continue practicing after their license/registration expires as a result of their inability to timely renew their license/registration due to the COVID-19 pandemic?

Answer: Previously, but the provision has terminated. Licensees and registrants whose license or registration expired during the proclamation period have until August 24, 2021 to renew their license/registration without a late penalty fee. On August 25, 2021, any license or registration that expired during the proclamation period and not renewed will be changed to "expired" status.

Question: Will the Board process applications for new licenses and registrations in a normal manner?

Answer: At this time, the Board does not anticipate any excursion from its normal processing, but as COVID-19 continues to present incredible challenges, Board staff may need to make adjustments in the Board's operations accordingly. The Board recognizes that new license/registration applications may be submitted as a means to assist with the pandemic in Iowa, so Board staff will make every effort to timely process new applications. The board's [online application portal](#) is available for every license/registration category of pharmacy employee.

BOARD VARIANCE/WAIVER REQUEST REVIEWS

Question: Will the Board continue to process variance/waiver requests that require Board approval?

Answer: The Board will continue to review any submitted waiver/various requests during its regular open session meetings.

Question: What should licensees do if they are unable to meet the granted delay in compliance with USP Chapter facility requirements due to delays caused by responding to the COVID-19 pandemic?

Answer: The Board's delayed compliance committee will consider extension requests for any granted delay that will expire within 90 days. The Board expects that licensees will attempt to comply with their granted delay, but acknowledges that pandemic circumstances may affect labor and financial resources. The committee will consider any request for extension that includes an

adjusted timeline. Requests should be sent by email to Christie Carlson at christie.carlson@iowa.gov who will handle submission for consideration. Licensees may continue to send requests after pandemic resolution, if needed.